INTRODUCTION
Pneumonia in elderly is a major public health problem causing significant morbidity and mortality. It represents the fifth leading cause of death in the elderly. 1 The increased incidence and severity of pneumonia among this age group is attributed to immunosenescence and underlying comorbid medical disorders. Furthermore, hospitalization itself is a strong predictor for pneumonia as the second most common nosocomial infection; with the risk increases proportional to the length of hospital stay.
Pneumonia Severity Index (PSI), 8 the Confusion, Urea, Respiratory rate, Blood pressure, age≥65 (CURB-65), 9 and the Systolic blood pressure, Multilobar infiltrates, Albumin, Respiratory rate, Tachycardia, Confusion, Oxygen and pH (SMART-COP) 10 scores.
Although, there are many assessment tools designed for risk stratification in CAP setting, there is no agreement on the optimum one. 11 Each score has its advantages and disadvantages but none of them was validated for use in HAP setting. Moreover, there is no other disease based validated scoring system in use for HAP. Thus, the patient cohorts recruited for HAP clinical trials are very heterogenous regarding mortality risk. This is a major limitation preventing proper randomization. 12 Lack of sufficient validity for the severity scores of HAP in elderly, limits their use in clinical and research settings.
The aim of this study was to compare the performance of the different pneumonia severity scores for predicting 30 days mortality, the use of vasopressors and the need for mechanical ventilation among elderly patients in both community and hospital acquired pneumonia groups.
PATIENTS AND METHODS
A case-control study was conducted in the out-patient as well as in-patient of the Geriatrics Department at Ain Shams University Hospital, Cairo, Egypt over a period of twelve months from August 2014 to July 2015.
Seventy one patients aged 60 years and older were recruited and subdivided into group (1) that included 41 participants suffering from CAP and group (2) including 30 participants suffering from HAP.
CAP was defined according to the criteria proposed by Fang et al.
13
: a) the presence of infiltrate in the admission chest x-ray; b) the presence of one or more major criteria (cough, mucopurulent or hemoptic expectoration, temperature >37.8 °C measured axillary); or c) at least two minor criteria (pleuritic chest pain, dyspnea, decreased level of consciousness, lung tissue consolidation detected by physical examination, or total leucocytes count ≥ 12000/ml). While, HAP was defined as pneumonia that occurred 48 hours or more after hospital admission and not incubating at the time of admission.
14 Exclusion criteria were pulmonary fibrosis, other infections e.g. urinary tract infection, skin and soft tissue infections etc, and malignancy.
At the time of initial evaluation, all participants were subjected to clinical assessment that included detailed personal and medical history, physical examination, and chest radiograph (postero-anterior and lateral views). Blood samples were collected for estimation of total leucocytes count, hemoglobin concentration, hematocrit, platelet count, fasting blood glucose, serum levels of Blood urea Nitrogen, Creatinine, Sodium, Potassium, Calcium, Phosphorus, Magnesium, total proteins, albumin, transaminases, and bilirubin. Arterial blood gases (ABGs) were also performed. Coexisting illnesses were diagnosed based on patients' self reports, data from medical record and the results of the previous investigations.
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Each patient was assessed for pneumonia severity using PSI, CURB-65, and SMART-COP scores.
PSI composed of 20 different parameters that include: age, sex, nursing home living, coexisting illnesses, physical examination findings, several laboratory, blood gas, and radiographic patterns. It is a five class scoring system stratified according to the increased mortality risk.
7
The CURB 65 index includes confusion, urea nitrogen (>7 mmol/l), respiratory rate (>30/min), and blood pressure (diastolic pressure <60 mm Hg or systolic blood pressure of <90 mm Hg).
8
SMART-COP was designed to predict the need for intensive respiratory or vasopressor support (IRVS) among hospitalized patients with CAP. Criteria included were systolic BP <90mmHg, Multilobar Chest X-ray involvement, Albumin <35 g/l, Respiratory rate≥ 30 br/min in age above 50, Tachycardia ≥125 b.p.m, new onset confusion, Oxygenation ≤ 60mmHg or O 2 sat ≤90% in age above 50, and PH < 7.35. Finally, the clinical outcomes i.e. hospital discharge, in hospital mortality, or 30 days mortality were recorded. The need for mechanical ventilation or vasopressor drugs were recorded.
Ethical consideration
Informed consent was taken from every elder participating in this study or his surrogate. The study methodology was approved by the Research Review Board of the Geriatrics and Gerontology Department, Faculty of medicine, Ain Shams University.
Statistical methods
The data were tabulated and statistical analyzed using SPSS program (version 16). Quantitative variables were presented in the form of means and standard deviation. Qualitative variables were presented in form of frequency tables. The comparison between quantitative variables was done using t test. Comparison between qualitative variables was done using Pearson's Chi square test. Statistical difference was accepted when p < 0.05. Receiver operating characteristic (ROC) curves were constructed. The area under each ROC curve was calculated to assess the ability of the assessed score to predict recorded outcomes.
RESULTS
A comparison between cases with CAP and cases with HAP regarding their demographic characteristics are shown in Table 1 . Both were matched for age and sex. Among patients with CAP the most common comorbidity was diabetes mellitus, followed by hypertension and Ischemic heart disease. Among the patients with HAP, the most common comorbidity was diabetes mellitus, followed by hypertension and cerebrovascular accidents.
Regarding the recorded outcomes, there was a significant difference between the two groups regarding 30 day mortality (p= 0.031). Twenty patients with HAP (66.67%) died within 30 days [10 (33.3%) of them died in hospital]. While, among cases with CAP seventeen (41.5 %) patients died within 30 days [10 (24.39%) of them died in hospital]. Moreover, there was a significant difference between the two groups regarding the use of vasopressor drugs but not regarding the use of mechanical ventilation. The three studied severity assessment scores were significantly higher among patients with HAP compared to those with CAP ( Table 1) .
Among the CAP group, the patients who died were older than the survivors; they had lower partial pressure of oxygen, serum albumin level, and score of Glasgow Coma Scale. Moreover, they had higher heart rate and higher PSI, CURB 65, and SMART-COP scores. Similarly, among the HAP group, the patients who died were older than the survivors; they had lower partial pressure of oxygen and score of Glasgow Coma Scale and higher heart rate, fasting blood glucose and higher PSI and SMART-COP scores. As regards the effect of comorbidity, the coexisting illnesses showed no significant difference between survivors and non survivors in both groups ( Table 2) . Among HAP group, PSI was the only tool with the ability to predict 30 day mortality, the use of mechanical ventilation but not the use of vasopressor drugs, while only SMART-COP and CURB 65 predicted the use of vasopressor drugs in this group.
Among HAP group, PSI had an area under the curve of 0.791 (95% CI; 0.625-0.959, p = 0.011*) for predicting 30 day mortality, had area under the curve equal to 0.790(95% CI; 0.626-0.955, p = 0.007*) for predicting the use of mechanical ventilation, and it was insignificant for predicting the use of vasopressor drugs (Figures 1-3) . For predicting the use of vasopressor drugs among HAP group, CURB 65 had area under the curve equal to 0.889 (95% CI; 0.713-1.056, p = 0.001*), and SMART-COP had area under the curve equal to 0.929 (95% CI; 0.827-1.031, p = 0.000*) (Figure 3 ). 
DISCUSSION
The aim of this study was to validate the use of PSI, CURB-65, and SMART-COP scores in HAP setting.
We examined the role of PSI, CURB-65, and SMART-COP scores as predictors of 30-day mortality in patients admitted because of CAP or developed HAP during their course of hospital stay. The ability to predict the need for Previous data reported that CAP related mortality in elderly was 10% in hospital and 13% on follow up at 30 days.
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Lower mortality rate was reported by Ewing et al. 18 it was (13.72% and 14.44%) in 2005, 2006 respectively. This is attributed to inclusion of adults aged 18 years and older.
There was a statistically significant difference between survivors and patients who died in the CAP group regarding their age. This agrees with previous studies [18] [19] [20] which reported that advanced age was a significant independent risk factor for mortality in CAP.
Among the CAP group, the patients who died had lower serum albumin level, and score of Glasgow Coma Scale. Moreover, they had higher heart rate. The same results were reported by Calle et al. 16 Previous validation studies reported that CAP related mortality was associated with higher PSI, 7 CURB 65, 8 and SMART-COP 9 scores. Similar results were reported in the present study. Among the CAP group, the patients who died had lower partial pressure of oxygen. Previous results confirmed that hypoxemia was associated with higher mortality for hospitalized CAP in other studies.
17,21
SMART-COP was the only score significant for predicting the use of vasopressor drugs in the CAP group (AUC= 0.956) and it performed better than PSI in predicting 30 day mortality (AUC = 0.751and 0.714 respectively). Similarly, it performed better than PSI for predicting the use of mechanical ventilation (AUC= 0.819 vs. 0.670).
In the SMART-COP validation study, 10 the SMART-COP was better than PSI and CURB 65 in predicting the receipt of intensive respiratory or vasopressor support AUC =0.87, 0.69, and 0.62 respectively.
According to Capelastegui et al. PSI had area under the curve (AUC) 0.888, 95% confidence interval (CI) 0.864-0.912); while CURB-65 had (AUC 0.870, 95% CI 0.844-0.895) in predicting 30-day mortality in CAP.
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In the current study, twenty patients with HAP (66.67%) died within 30 days with 10 (33.3%) of them died in hospital. Previous data suggested that the in-hospital mortality in HAP was 51.5%. 23 According to Burton et al., mortality rate was 29% in patients with confirmed HAP, and 19% in patients with suspected HAP.
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In the present study, only PSI had the prognostic power to predict 30 day mortality and the use of mechanical ventilation in the HAP group. Neither CURB-65 nor SMART-COP had the prognostic power to predict 30 day mortality or the use of mechanical ventilation in the HAP group.
Carrabba et al. reported that the 30-day mortality rate was 9.0% in the CAP group and 24.1% in the healthcare associated pneumonia (HCAP) group. In the HCAP group, the PSI had AUC of 0.68 and performed better than the CURB-65 score (AUC =0.62).
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This is in accordance with Fang et al., 26 who demonstrated that PSI had moderate ability to discriminate survivors and the died patients at 30 days, and predicting the need for ICU admission. The PSI had the highest sensitivity to predicting mortality (AUC=0.70), followed by CURB-65 (AUC= 0.66). For predicting ICU admission on day 3 and day 14, the SMART-COP had AUC of 0.84 and 0.82 respectively.
Our study had several limitations; importantly this was a small single site observational study. With the small sample size, its statistical power might be insufficient.
In conclusion, this study demonstrated high 30 day mortality among elderly in both CAP and HAP groups. Among CAP group, the PSI, CURB 65, and SMART-COP scores allowed good discrimination for predicting 30 day mortality. Neither CURB-65 nor PSI allowed discrimination in predicting the use of vasopressor support. Among HAP group, the PSI allowed good discrimination for predicting 30 day mortality and the use of mechanical ventilation. Both CURB-65 and SMART-COP but not the PSI allowed the prediction of using vasopressor support in HAP group.
